Clinical trial NCT04589845: Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Official title: Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Solid Tumors
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2020-10-19
Enrollment: 920
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy
* Measurable disease as defined by RECIST v1.1, RANO, or INRC
* Performance status as follows: Participants aged ≥ 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participants aged 16 to \< 18 years: Karnofsky score ≥ 50%; Participants aged \< 16 years: Lansky score ≥ 50%
* For participants aged ≥ 18 and \< 18 years: adequate hematologic and end-organ function
* Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment
* Adequate recovery from most recent systemic or local treatment for cancer
* Life expectancy ≥ 8 weeks
* Ability to comply with the study protocol, in the investigator's judgment
* For female participants of childbearing potential: Negative serum pregnancy test ≤ 14 days prior to initiating study treatment, agreement to remain abstinent or use single or combined contraception methods that result in a failure rate of \< 1% per year for the period defined in the cohort-specific inclusion criteria; and agreement to refrain from donating eggs during the same period
* For male participants: Willingness to remain abstinent or use acceptable methods of contraception as defined in the cohort-specific inclusion criteria
* In addition to the general inclusion criteria above, participants must meet all of the cohort-specific inclusion criteria for the respective cohort

Exclusion Criteria:

* Current participation or enrollment in another therapeutic clinical trial
* Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment
* Whole brain radiotherapy within 14 days prior to start of study treatment
* Stereotactic radiosurgery within 7 days prior to start of study treatment
* Pregnant or breastfeeding, or intending to become pregnant during the study
* History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study
* Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
* History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy
* In addition to the general exclusion criteria above, in order to be enrolled in a treatment cohort of the study, participants must not meet any of the cohort-specific exclusion criteria

Primary outcomes:
measure: All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
timeFrame: Approximately up to 12 years
Secondary outcomes:
measure: All Cohorts: IRC-assessed Duration of Response (DOR) per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: All Cohorts: IRC-assessed Clinical Benefit Rate (CBR) per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: All Cohorts: IRC-assessed Progression-free Survival (PFS) per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: All Cohorts: Investigator (INV)-assessed ORR per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: All Cohorts: INV-assessed DOR per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: All Cohorts: INV-assessed CBR per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: All Cohorts: INV-assessed PFS per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: All Cohorts: IRC- and INV-assessed Time to Central Nervous System (CNS) Progression per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: All Cohorts: Overall Survival (OS)
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-ORR per Response Assessment in Neuro-oncology (RANO)
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-DOR per RANO
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-CBR per RANO
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-PFS per RANO
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: INV-assessed CNS-ORR per RANO
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: INV-assessed CNS-DOR per RANO
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: INV-assessed CNS-CBR per RANO
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: INV-assessed CNS-PFS per RANO
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed ORR per International Neuroblastoma Response Criteria (INRC)
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed DOR per INRC
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed CBR per INRC
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed PFS per INRC
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed ORR per INRC
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed DOR per INRC
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed CBR per INRC
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed PFS per INRC
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: IRC-assessed Intracranial (IC)-ORR per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: IRC-assessed IC-DOR per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: IRC-assessed IC-CBR per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: IRC-assessed IC-PFS Rate per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: INV-assessed IC-ORR per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: INV-assessed IC-DOR per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: INV-assessed IC-CBR per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: Cohorts A, B, C, D, I, J, K: INV-assessed IC-PFS Rate per RECIST v1.1
timeFrame: Approximately up to 12 years
measure: Cohorts A and B: Percentage of Participants With Confirmed Deterioration as Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
timeFrame: Approximately up to 12 years
measure: Cohorts A and B: Change From Baseline in the EORTC-QLQ-C30 Total Score
timeFrame: Approximately up to 12 years
measure: Cohorts A and B: Percentage of Participants With a Clinical Meaningful Change on the Global Health Status, Physical Functioning, and Role Functioning Scores From the EORTC QLQ-C30
timeFrame: Approximately up to 12 years
measure: Cohorts A and B: Time to Confirmed Symptom Onset or Worsening From Tumor-related Symptom Scores From the EORTC QLQ-C30 and EORTC Item Library 71 (IL71)
timeFrame: Approximately up to 12 years
measure: All Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: Approximately up to 12 years
Other outcomes:
Locations:
city: Daphne
country: United States
facility: Southern Cancer Center
state: Alabama
city: Goodyear
country: United States
facility: Western Regional Medical Center at Cancer Treatment Centers of America
state: Arizona
city: Duarte
country: United States
facility: City of Hope National Medical Center
state: California
city: Los Angeles
country: United States
facility: Kaiser Permanente Los Angeles
state: California
city: Los Angeles
country: United States
facility: USC Norris Cancer Center
state: California
city: Newport Beach
country: United States
facility: Hoag Memorial Hospital
state: California
city: Sacramento
country: United States
facility: UC Davis Comprehensive Cancer Center
state: California
city: San Francisco
country: United States
facility: University of California at San Francisco
state: California
city: Santa Monica
country: United States
facility: Sarcoma Oncology Center
state: California
city: Aurora
country: United States
facility: Children's Hospital Colorado
state: Colorado
city: Newark
country: United States
facility: Christiana Care Health Srvcs
state: Delaware
city: Gainesville
country: United States
facility: University of Florida
state: Florida
city: Miami
country: United States
facility: Miami Cancer Institute of Baptist Health, Inc.
state: Florida
city: Ocala
country: United States
facility: Ocala Oncology Center
state: Florida
city: Athens
country: United States
facility: University Cancer & Blood Center, LLC
state: Georgia
city: Boise
country: United States
facility: St. Alphonsus
state: Idaho
city: Zion
country: United States
facility: Cancer Treatment Centers of America; Eastern Regional Medical Center
state: Illinois
city: Zion
country: United States
facility: Midwestern Regional Med Center
state: Illinois
city: Lafayette
country: United States
facility: Horizon Oncology Research, Inc.
state: Indiana
city: Scarborough
country: United States
facility: New England Cancer Specialists
state: Maine
city: Silver Spring
country: United States
facility: Maryland Hematology & Oncology. P.A.
state: Maryland
city: Ann Arbor
country: United States
facility: St. Joseph Mercy Hospital
state: Michigan
city: Detroit
country: United States
facility: Henry Ford Health System
state: Michigan
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
city: Saint Louis Park
country: United States
facility: Metro-Minnesota Community Oncology Research Consortium
state: Minnesota
city: Saint Louis
country: United States
facility: Washington University
state: Missouri
city: Billings
country: United States
facility: Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana
state: Montana
city: Omaha
country: United States
facility: Nebraska Methodist Hospital
state: Nebraska
city: Las Vegas
country: United States
facility: Comprehensive Cancer Centers of Nevada - Eastern Avenue
state: Nevada
city: Lebanon
country: United States
facility: Dartmouth Hitchcock Medical Center
state: New Hampshire
city: New Brunswick
country: United States
facility: Rutgers Cancer Institute of New Jersey
state: New Jersey
city: Albuquerque
country: United States
facility: University of New Mexico
state: New Mexico
city: Bronx
country: United States
facility: Montefiore Einstein Center for Cancer Care
state: New York
city: Bronx
country: United States
facility: Eastchester Center for Cancer Care
state: New York
city: New York
country: United States
facility: National Translational Research Group
state: New York
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Port Jefferson Station
country: United States
facility: New York Cancer and Blood Specialists - Setauket Medical Oncology
state: New York
city: Cincinnati
country: United States
facility: Barrett Cancer Center
state: Ohio
city: Cincinnati
country: United States
facility: Oncology Hematology Care Inc
state: Ohio
city: Portland
country: United States
facility: Providence Portland Medical Center
state: Oregon
city: Broomall
country: United States
facility: Consultants in Medical Oncology and Hematology
state: Pennsylvania
city: Horsham
country: United States
facility: Alliance Cancer Specialists
state: Pennsylvania
city: Leesburg
country: United States
facility: Virginia Cancer Specialists - Leesburg
state: Pennsylvania
city: Philadelphia
country: United States
facility: Cancer Treatment Centers of America
state: Pennsylvania
city: Philadelphia
country: United States
facility: The Children's Hospital of Philadelphia
state: Pennsylvania
city: Greenville
country: United States
facility: PRISMA Health - Greenville
state: South Carolina
city: Germantown
country: United States
facility: The West Clinic; West Cancer Center
state: Tennessee
city: Germantown
country: United States
facility: The West Clinic
state: Tennessee
city: Memphis
country: United States
facility: St. Jude Children'S Research Hospital
state: Tennessee
city: Austin
country: United States
facility: Texas Oncology - Central South
state: Texas
city: Dallas
country: United States
facility: Mary Crowley Medical Research Center
state: Texas
city: Dallas
country: United States
facility: Texas Oncology - Baylor Charles A. Sammons Cancer Center
state: Texas
city: Fort Worth
country: United States
facility: Cook Childrens Medical Center
state: Texas
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
city: Tyler
country: United States
facility: Texas Oncology- Northeast Texas
state: Texas
city: Tacoma
country: United States
facility: Northwest Medical Specialties, PLLC
state: Washington
city: Milwaukee
country: United States
facility: Froedtert and The Medical College of Wisconsin
state: Wisconsin
city: Darlinghurst
country: Australia
facility: Kinghorn Cancer Centre
state: New South Wales
city: Randwick
country: Australia
facility: Sydney Children's Hospital
state: New South Wales
city: Tiwi
country: Australia
facility: Royal Darwin Hospital
state: Northern Territory
city: Woolloongabba
country: Australia
facility: Princess Alexandra Hospital
state: Queensland
city: Melbourne
country: Australia
facility: Peter MacCallum Cancer Centre
state: Victoria
city: Parkville
country: Australia
facility: Royal Children's Hospital
state: Victoria
city: Bruxelles
country: Belgium
facility: Cliniques Universitaires St-Luc
city: Charleroi
country: Belgium
facility: GHdC Site Les Viviers
city: Edegem
country: Belgium
facility: UZ Antwerpen
city: Gent
country: Belgium
facility: UZ Gent
city: Leuven
country: Belgium
facility: UZ Leuven Gasthuisberg
city: Porto Alegre
country: Brazil
facility: Hospital Moinhos de Vento
state: Rio Grande Do Sul
city: Sao Paulo
country: Brazil
facility: Hospital Sírio-Libanês
state: São Paulo
city: Sao Paulo
country: Brazil
facility: Hospital Sírio-Libanês
state: São Paulo
city: Sao Paulo
country: Brazil
facility: Hospital A. C. Camargo
state: São Paulo
city: Sao Paulo
country: Brazil
facility: Clínica Onco Star - Rede D'Or
state: São Paulo
city: Vancouver
country: Canada
facility: BC Cancer ? Vancouver
state: British Columbia
city: London
country: Canada
facility: London Health Sciences Centre · Victoria Hospital
state: Ontario
city: Ottawa
country: Canada
facility: The Ottawa Hospital - General Campus
state: Ontario
city: Toronto
country: Canada
facility: The Hospital for Sick Children
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Center
state: Ontario
city: Montreal
country: Canada
facility: McGill University Health Center
state: Quebec
city: Beijing
country: China
facility: Beijing Cancer Hospital
city: Beijing
country: China
facility: Beijing Children's Hospital, Capital Medical University
city: Changchun City
country: China
facility: The First Hospital of Jilin University
city: Changchun
country: China
facility: Jilin Cancer Hospital
city: Chengdu City
country: China
facility: West China Hospital - Sichuan University
city: Shanghai City
country: China
facility: Shanghai East Hospital
city: Shanghai
country: China
facility: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
city: Shanghai
country: China
facility: Zhongshan Hospital Fudan Unvierstiy
city: Tianjin
country: China
facility: Tianjin Cancer Hospital
city: Xi'an
country: China
facility: First Affiliated Hospital of Medical College of Xi'an Jiaotong University
city: Aalborg
country: Denmark
facility: Aalborg Universitetshospital
city: Aarhus N
country: Denmark
facility: Aarhus Universitetshospital
city: København Ø
country: Denmark
facility: Rigshospitalet
city: Bordeaux
country: France
facility: Institut Bergonie
city: Lille
country: France
facility: Centre Oscar Lambret
city: Lyon
country: France
facility: Centre Leon Berard
city: Marseille
country: France
facility: Hopital de la Timone
city: Toulouse
country: France
facility: Institut Universitaire du Cancer de Toulouse-Oncopole
city: Villejuif
country: France
facility: Institut de Cancerologie Gustave-Roussy (IGR)
city: Essen
country: Germany
facility: Uniklinik Essen
city: Freiburg im Breisgau
country: Germany
facility: Universitätsklinikum Freiburg Medizinische Klinik Innere Medizin I
city: Göttingen
country: Germany
facility: Georg-August-Uniklinik
city: Hamburg
country: Germany
facility: Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
city: Hannover
country: Germany
facility: Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und Hepatologie
city: Heidelberg
country: Germany
facility: Klinik Kinderheikunde I des Zentrums für Kinder- und Jugendmedizin, Universität Heidelberg
city: Heilbronn
country: Germany
facility: SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III
city: Mönchengladbach
country: Germany
facility: Praxis für Hämatologie, Onkologie und Palliativmedizin
city: München
country: Germany
facility: Klinikum der Universität München, Campus Großhadern
city: Ulm
country: Germany
facility: Universtitätsklinikum Ulm
city: Würzburg
country: Germany
facility: Uniklinikum, Comprehensive Cancer Center Mainfranken
city: Hong Kong
country: Hong Kong
facility: Hong Kong Children's Hospital
city: Shatin
country: Hong Kong
facility: Prince of Wales Hospital
city: Haifa
country: Israel
facility: Rambam Health Care Campus
city: Jerusalem
country: Israel
facility: Hadassah University Hospital - Ein Kerem
city: Petach Tikva
country: Israel
facility: Rabin MC
city: Ramat Gan
country: Israel
facility: Sheba Medical Center
city: Tel Aviv
country: Israel
facility: Sourasky / Ichilov Hospital
city: Napoli
country: Italy
facility: Istituto Nazionale Tumori Fondazione G. Pascale
state: Campania
city: Roma
country: Italy
facility: Ospedale Pediatrico Bambino Gesù - IRCCS
state: Lazio
city: Roma
country: Italy
facility: Policlinico Universitario Agostino Gemelli IRCCS
state: Lazio
city: Brescia
country: Italy
facility: Asst Degli Spedali Civili Di Brescia
state: Lombardia
city: Milano
country: Italy
facility: Irccs Istituto Nazionale Dei Tumori (Int)
state: Lombardia
city: Milano
country: Italy
facility: Istituto Nazionale Tumori di Milano
state: Lombardia
city: Torino
country: Italy
facility: Dipartimento di Scienze Pediatriche Adolescenza
state: Piemonte
city: Firenze
country: Italy
facility: Azienda Ospedaliera Meyer
state: Toscana
city: Siena
country: Italy
facility: Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
state: Toscana
city: Chiba
country: Japan
facility: National Cancer Center Hospital East
city: Osaka
country: Japan
facility: Kindai University Hospital
city: Tokyo
country: Japan
facility: National Cancer Center Hospital
city: Gyeonggi-do
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital- Adult Site
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital- Pediatric Site
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center- Adult Site
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center- Pediatric Site
city: Utrecht
country: Netherlands
facility: Prinses Maxima Centrum
city: Auckland
country: New Zealand
facility: Auckland City Hospital, Cancer and Blood Research
city: Gda?sk
country: Poland
facility: Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
city: Warszawa
country: Poland
facility: Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad
city: Porto
country: Portugal
facility: IPO do Porto
city: San Juan
country: Puerto Rico
facility: PanOncology Trials
city: Moscow
country: Russian Federation
facility: Federal Scientific and Clinical Center for Pediatric Hematology, Oncology and Immunology
city: Moscow
country: Russian Federation
facility: SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"
city: Saint Petersburg
country: Russian Federation
facility: FSBI"National Medical Research Center of Oncology named after N.N.Petrov" MHRF
city: Singapore
country: Singapore
facility: National University Hospital
city: Singapore
country: Singapore
facility: National Cancer Centre
city: Johannesburg
country: South Africa
facility: Medical Oncology Centre of Rosebank
city: Johannesburg
country: South Africa
facility: WITS Clinical Research Site PPDS
city: Pretoria
country: South Africa
facility: Wilgers Oncology Centre
city: Esplugues De Llobregas
country: Spain
facility: Hospital Sant Joan De Deu
state: Barcelona
city: Barcelona
country: Spain
facility: Vall d'Hebron Institute of Oncology (VHIO), Barcelona
city: Barcelona
country: Spain
facility: Vall d?Hebron Institute of Oncology (VHIO), Barcelona
city: Madrid
country: Spain
facility: Hospital Infantil Universitario Nino Jesus
city: Madrid
country: Spain
facility: Clinica Universidad de Navarra Madrid
city: Madrid
country: Spain
facility: START Madrid-FJD, Hospital Fundacion Jimenez Diaz
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
city: Madrid
country: Spain
facility: START Madrid. Centro Integral Oncologico Clara Campal
city: Valencia
country: Spain
facility: Hospital Universitario la Fe
city: Basel
country: Switzerland
facility: Universitätsspital Basel (USB)
city: Bellinzona
country: Switzerland
facility: Ospedale Regionale di Bellinzona Medizin Onkologie
city: Bern
country: Switzerland
facility: Inselspital, Klinik und Poliklinik für Medizinische Onkologie
city: Zürich
country: Switzerland
facility: Unversitätsspital Zürich
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital
city: Taipei City
country: Taiwan
facility: Taipei Veterans General Hospital
city: Taoyuan County
country: Taiwan
facility: Chang Gung Memorial Hospital-Linkou
city: Zhongzheng Dist.
country: Taiwan
facility: National Taiwan University Hospital
city: Glasgow
country: United Kingdom
facility: Beatson West of Scotland Cancer Centre
city: London
country: United Kingdom
facility: University College London Hospital
city: London
country: United Kingdom
facility: Guys and St Thomas NHS Foundation Trust, Guys Hospital
city: Manchester
country: United Kingdom
facility: Royal Manchester Children?s Hospital
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References: